Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Studies show treatment success for chronic hepatitis C may be predicted by rapid virological response

The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR).

17 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

12 Jan 2010

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.

12 Jan 2010

Sudden Cardiac Arrest Foundation announces first virtual affiliate of its National Survivor Network

The Sudden Cardiac Arrest Foundation announced today the first virtual affiliate of its National Survivor Network(TM) at the National Association of EMS Physicians annual conference.

9 Jan 2010

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 “BRAF Inhibitor in Melanoma” (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

9 Jan 2010

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

A new national survey reveals that while almost all Canadians understand the importance of getting checked for colon cancer, most have not had a screening test and are confused about how and when it should happen.

8 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010

Data highlights importance of follow-up exams for patients with history of advanced adenomas

A new study examines the occurrence of interval colorectal cancer despite regular colonoscopy and highlights the importance of close follow-up for patients who have a history of advanced adenomas, which are precancerous polyps.

7 Jan 2010

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, and Genetic Technologies Ltd. (ASX: GTG; NASDAQ: GENE), the leading private genetic testing laboratory in Australia, today announced an exclusive distribution and services agreement.

7 Jan 2010

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).

6 Jan 2010

Wisconsin rural hospitals hope for federal money to offset state Medicaid cut

Wisconsin's rural hospitals hope to offset a state Medicaid cut with a tax that would bring more federal money to the hospitals. The proposed tax on the state's 59 'critical access' hospitals, all in rural areas, would prevent the hospitals from closing important services, officials say.

5 Jan 2010

Researchers study the effectiveness of colonoscopy in preventing colorectal cancer

The prevalence of left-sided advanced colorectal neoplasms was lower in participants in a community setting, but not right-sided advanced neoplams, who had received a colonoscopy in the preceding 10 years, according to a new study published online December 30 in the Journal of the National Cancer Institute.

31 Dec 2009

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Poniard Pharmaceuticals sells common shares for $6.5 million

Poniard Pharmaceuticals today announced the sale of 3,489,728 of its common shares to Azimuth Opportunity Ltd. for net proceeds of approximately $6.5 million, or approximately $1.87 per share, under its existing committed equity financing facility with Azimuth.

23 Dec 2009

MSH6 mutation carriers at elevated risk for colorectal, endometrial and lynch syndrome cancers

People carrying the germ-line MSH6 mutation are at high risk by age 80 years for colorectal and endometrial cancers and any cancer associated with Lynch syndrome, according to a new study published online December 22 in the Journal of the National Cancer Institute.

23 Dec 2009

High prevalence of type 2 diabetes may be linked to excess niacin intake

Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time.

23 Dec 2009

First robot-assisted lung-tumor surgery performed at UT Southwestern Medical Center

When Craig Harrison found out he would be the first patient in North Texas to have robot-assisted lung-tumor surgery, an operation performed at UT Southwestern Medical Center, he wasn't nervous at all.

22 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Joe Chimera, the 25th person to receive MEP Certification from PHII

The Population Health Impact Institute (PHII) is pleased to announce that Joe Chimera, Ph.D., is the 25th person to receive the Methods Evaluation Process (MEP) Certification.

18 Dec 2009

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Studies show treatment success for chronic hepatitis C may be predicted by rapid virological response

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

Sudden Cardiac Arrest Foundation announces first virtual affiliate of its National Survivor Network

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Data highlights importance of follow-up exams for patients with history of advanced adenomas

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Wisconsin rural hospitals hope for federal money to offset state Medicaid cut

Researchers study the effectiveness of colonoscopy in preventing colorectal cancer

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Poniard Pharmaceuticals sells common shares for $6.5 million

MSH6 mutation carriers at elevated risk for colorectal, endometrial and lynch syndrome cancers

High prevalence of type 2 diabetes may be linked to excess niacin intake

First robot-assisted lung-tumor surgery performed at UT Southwestern Medical Center

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Joe Chimera, the 25th person to receive MEP Certification from PHII

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in